Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 53

1.

Defending against smallpox: a focus on vaccines.

Voigt EA, Kennedy RB, Poland GA.

Expert Rev Vaccines. 2016 Sep;15(9):1197-211. doi: 10.1080/14760584.2016.1175305. Epub 2016 Apr 28.

PMID:
27049653
2.

A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA Smallpox Vaccine (IMVAMUNE) in 18-40 Year Old Subjects with Diagnosed Atopic Dermatitis.

Greenberg RN, Hurley MY, Dinh DV, Mraz S, Vera JG, von Bredow D, von Krempelhuber A, Roesch S, Virgin G, Arndtz-Wiedemann N, Meyer TP, Schmidt D, Nichols R, Young P, Chaplin P.

PLoS One. 2015 Oct 6;10(10):e0138348. doi: 10.1371/journal.pone.0138348. eCollection 2015 Oct 6. Erratum in: PLoS One. 2015;10(11):e0142802. Hurley, Yadira [corrected to Hurley, Maria Yadira].

3.

Atopic dermatitis in children: clinical features, pathophysiology, and treatment.

Lyons JJ, Milner JD, Stone KD.

Immunol Allergy Clin North Am. 2015 Feb;35(1):161-83. doi: 10.1016/j.iac.2014.09.008. Epub 2014 Nov 21. Review.

4.

Enhanced efficacy of cidofovir combined with vaccinia immune globulin in treating progressive cutaneous vaccinia virus infections in immunosuppressed hairless mice.

Smee DF, Dagley A, Downs B, Hagloch J, Tarbet EB.

Antimicrob Agents Chemother. 2015 Jan;59(1):520-6. doi: 10.1128/AAC.04289-14. Epub 2014 Nov 10.

5.

Vaccinia virus binds to the scavenger receptor MARCO on the surface of keratinocytes.

MacLeod DT, Nakatsuji T, Wang Z, di Nardo A, Gallo RL.

J Invest Dermatol. 2015 Jan;135(1):142-50. doi: 10.1038/jid.2014.330. Epub 2014 Aug 4.

6.

Molluscum contagiosum in a pediatric American Indian population: incidence and risk factors.

McCollum AM, Holman RC, Hughes CM, Mehal JM, Folkema AM, Redd JT, Cheek JE, Damon IK, Reynolds MG.

PLoS One. 2014 Jul 29;9(7):e103419. doi: 10.1371/journal.pone.0103419. eCollection 2014 Jul 29.

7.

Are we there yet? The smallpox research agenda using variola virus.

Damon IK, Damaso CR, McFadden G.

PLoS Pathog. 2014 May 1;10(5):e1004108. doi: 10.1371/journal.ppat.1004108. eCollection 2014 May 1. No abstract available.

8.

Intrafamilial transmission of Vaccinia virus during a bovine Vaccinia outbreak in Brazil: a new insight in viral transmission chain.

Pereira Oliveira G, Tavares Silva Fernandes A, Lopes de Assis F, Augusto Alves P, Moreira Franco Luiz AP, Barcelos Figueiredo L, Costa de Almeida CM, Pires Ferreira Travassos CE, de Souza Trindade G, Santos Abrahão J, Geessien Kroon E.

Am J Trop Med Hyg. 2014 Jun;90(6):1021-3. doi: 10.4269/ajtmh.13-0621. Epub 2014 Mar 10.

9.
10.

Use of a recombinant vaccinia virus expressing interferon gamma for post-exposure protection against vaccinia and ectromelia viruses.

Holechek SA, Denzler KL, Heck MC, Schriewer J, Buller RM, Legrand FA, Verardi PH, Jones LA, Yilma T, Jacobs BL.

PLoS One. 2013 Oct 17;8(10):e77879. doi: 10.1371/journal.pone.0077879. eCollection 2013 Oct 17.

11.

Efficacy of tecovirimat (ST-246) in nonhuman primates infected with variola virus (Smallpox).

Mucker EM, Goff AJ, Shamblin JD, Grosenbach DW, Damon IK, Mehal JM, Holman RC, Carroll D, Gallardo N, Olson VA, Clemmons CJ, Hudson P, Hruby DE.

Antimicrob Agents Chemother. 2013 Dec;57(12):6246-53. doi: 10.1128/AAC.00977-13. Epub 2013 Oct 7.

12.

Comorbidity in Atopic Dermatitis.

Simpson EL.

Curr Dermatol Rep. 2012 Mar 1;1(1):29-38.

13.

Safety, immunogenicity, and surrogate markers of clinical efficacy for modified vaccinia Ankara as a smallpox vaccine in HIV-infected subjects.

Greenberg RN, Overton ET, Haas DW, Frank I, Goldman M, von Krempelhuber A, Virgin G, Bädeker N, Vollmar J, Chaplin P.

J Infect Dis. 2013 Mar 1;207(5):749-58. doi: 10.1093/infdis/jis753. Epub 2012 Dec 7.

14.

Epitope mapping by random peptide phage display reveals essential residues for vaccinia extracellular enveloped virion spread.

He Y, Wang Y, Struble EB, Zhang P, Chowdhury S, Reed JL, Kennedy M, Scott DE, Fisher RW.

Virol J. 2012 Sep 24;9:217. doi: 10.1186/1743-422X-9-217.

15.

Progressive vaccinia: case description and laboratory-guided therapy with vaccinia immune globulin, ST-246, and CMX001.

Lederman ER, Davidson W, Groff HL, Smith SK, Warkentien T, Li Y, Wilkins KA, Karem KL, Akondy RS, Ahmed R, Frace M, Shieh WJ, Zaki S, Hruby DE, Painter WP, Bergman KL, Cohen JI, Damon IK.

J Infect Dis. 2012 Nov;206(9):1372-85. doi: 10.1093/infdis/jis510. Epub 2012 Aug 16.

16.

Immune modulation in primary vaccinia virus zoonotic human infections.

Silva Gomes JA, de Araújo FF, de Souza Trindade G, Quinan BR, Drumond BP, Ferreira JM, Mota BE, Nogueira ML, Kroon EG, Santos Abrahão J, Côrrea-Oliveira R, da Fonseca FG.

Clin Dev Immunol. 2012;2012:974067. doi: 10.1155/2012/974067. Epub 2011 Dec 20.

17.

Inhibition of cowpox virus and monkeypox virus infection by mitoxantrone.

Altmann SE, Smith AL, Dyall J, Johnson RF, Dodd LE, Jahrling PB, Paragas J, Blaney JE.

Antiviral Res. 2012 Feb;93(2):305-8. doi: 10.1016/j.antiviral.2011.12.001. Epub 2011 Dec 11.

18.

Therapy and long-term prophylaxis of vaccinia virus respiratory infections in mice with an adenovirus-vectored interferon alpha (mDEF201).

Smee DF, Wong MH, Russell A, Ennis J, Turner JD.

PLoS One. 2011;6(10):e26330. doi: 10.1371/journal.pone.0026330. Epub 2011 Oct 13.

19.

Ectromelia virus infections of mice as a model to support the licensure of anti-orthopoxvirus therapeutics.

Parker S, Siddiqui AM, Painter G, Schriewer J, Buller RM.

Viruses. 2010 Sep;2(9):1918-32. doi: 10.3390/v2091918. Epub 2010 Sep 3.

20.

Historical perspectives in the development of antiviral agents against poxviruses.

De Clercq E.

Viruses. 2010 Jun;2(6):1322-39. doi: 10.3390/v2061322. Epub 2010 Jun 14.

Supplemental Content

Support Center